Suzhou Ribo Life Science Co., Ltd.

苏州瑞博生物技术股份有限公司

06938.HK

Develops siRNA-based oligonucleotide therapeutics, with a pipeline of seven clinical-stage drug candidates across cardiovascular, metabolic, renal and liver diseases, including a lead FXI-targeting siRNA for thrombotic diseases; operates in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Particular sales arrangements
• Capacity and utilisation
• Losses and path to profitability
• Net current liabilities or net liabilities
• Cash burn and runway
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Chapter 18A biotech